NASDAQ:CTMX

Cytomx Therapeutics Stock Insider Trading

etoro logo Buy CTMX
*Your capital is at risk
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026

CytomX Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 8.56. In total, the insiders bought 9.01M and sold 616.05K CTMX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
8.56
Buy 9.01M shares
Sell 616.05K shares
77% Buy Activity
Negligible or No Correlation
Sell Signal Low Confidence
Mar 17, 2026

Analysis Breakdown:

  • Weakened by a contradictory positive Insider Power Score.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jun 13, 2025
Buy
Common Stock
M-Exempt
Belvin Marcia
SVP, Chief Scientific Officer
Officer 37 500
Value: $103.1K
Jun 13, 2025
Buy
Performance Stock Units
M-Exempt
Ogden Christopher
Chief Financial Officer
C-Suite Officer 37 500
Value: $103.1K
Jun 13, 2025
Sell
Common Stock
S-Sale
Ogden Christopher
Chief Financial Officer
C-Suite Officer 1 641
Value: $5K
Jun 13, 2025
Buy
Common Stock
M-Exempt
Ogden Christopher
Chief Financial Officer
C-Suite Officer 37 500
Value: $103.1K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Su Zhen
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Young Matthew P.
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Mohindru Mani
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Meyers James R
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Jones Elaine V
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Gilbert Halley E
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Ashworth Alan
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Ashworth Alan
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Gilbert Halley E
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Jones Elaine V
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Meyers James R
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Mohindru Mani
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Young Matthew P.
Director
Director 38 000
Value: $107.2K
Jun 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Su Zhen
Director
Director 38 000
Value: $107.2K
Mar 18, 2025
Sell
Common Stock
S-Sale
Mccarthy Sean A.
CEO
CEO / President 37 656
Value: $22.6K
Mar 18, 2025
Sell
Common Stock
S-Sale
Ogden Christopher
Chief Financial Officer
C-Suite Officer 8 551
Value: $5K
Mar 18, 2025
Sell
Common Stock
S-Sale
Chu Yu-waye
Chief Medical Officer
Officer 4 025
Value: $2K
Mar 18, 2025
Sell
Common Stock
S-Sale
Rowland Lloyd A
General Counsel
Officer 10 203
Value: $6K
Mar 18, 2025
Sell
Common Stock
S-Sale
Belvin Marcia
SVP, Chief Scientific Officer
Officer 19 512
Value: $11.7K
Mar 18, 2025
Sell
Common Stock
S-Sale
Belvin Marcia
SVP, Chief Scientific Officer
Officer 19 512
Value: $11.7K
Mar 18, 2025
Sell
Common Stock
S-Sale
Rowland Lloyd A
General Counsel
Officer 10 203
Value: $6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT CYTOMX THERAPEUTICS
CytomX Therapeutics
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE